Compared to Estimates, Amicus Therapeutics (FOLD) Q4 Earnings: A Look at Key Metrics

For the quarter ended December 2024, Amicus Therapeutics (FOLD) reported revenue of $149.71 million, up 30.1% over the same period last year. EPS came in at $0.09, compared to -$0.11 in the year-ago quarter.The reported revenue represents a surprise of -0.13% over the Zacks Consensus Estimate of $149.89 million. With the consensus EPS estimate being $0.10, the EPS surprise was -10.00%.While investors closely watch year-over-year changes in headline numbers -- revenue and earnings -- and how they compare to Wall Street expectations to determine their next course of action, some key metrics always provide a better insight into a company's underlying performance.Since these metrics play a crucial role in driving the top- and bottom-line numbers, comparing them with the year-ago numbers and what analysts estimated about them helps investors better project a stock's price performance.Here is how Amicus Therapeutics performed in the just reported quarter in terms of the metrics most widely monitored and projected by Wall Street analysts: Geographic net product sales- Ex-U.S. $87.26 million compared to the $94.04 million average estimate based on two analysts. The reported number represents a change of +21.4% year over year. Geographic net product sales- U.S. $62.44 million versus $55.85 million estimated by two analysts on average. Compared to the year-ago quarter, this number represents a +44.6% change. Net product sales- Pombiliti + Opfolda: $22.21 million versus the six-analyst average estimate of $22.35 million. Net product sales- Galafold: $127.50 million versus the six-analyst average estimate of $140.98 million. The reported number represents a year-over-year change of +19.6%. View all Key Company Metrics for Amicus Therapeutics here>>>Shares of Amicus Therapeutics have returned +0.2% over the past month versus the Zacks S&P 500 composite's +2.6% change. The stock currently has a Zacks Rank #2 (Buy), indicating that it could outperform the broader market in the near term.5 Stocks Set to DoubleEach was handpicked by a Zacks expert as the #1 favorite stock to gain +100% or more in 2024. While not all picks can be winners, previous recommendations have soared +143.0%, +175.9%, +498.3% and +673.0%.Most of the stocks in this report are flying under Wall Street radar, which provides a great opportunity to get in on the ground floor.Today, See These 5 Potential Home Runs >>Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report Amicus Therapeutics, Inc. (FOLD): Free Stock Analysis ReportTo read this article on Zacks.com click here.Zacks Investment ResearchWeiter zum vollständigen Artikel bei Zacks Weiter zum vollständigen Artikel bei Zacks